DDInter1202 DDInter1376
Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several decades, with added antiparasitic properties that set it apart from many other antibacterial drugs, allowing it to treat a wide variety of infections. It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Metronidazole {u} (Compound) resembles {v} (Compound) Tinidazole
Metronidazole {u} (Compound) binds {v} (Gene) CYP2C8
Metronidazole {u} (Compound) upregulates {v} (Gene) ZNF586
Metronidazole {u} (Compound) is included by {v} (Pharmacologic Class) Nitroimidazoles
Metronidazole {u} (Compound) causes {v} (Side Effect) Loss of libido
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Atomoxetine
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tetrabenazine
Metronidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolate mofetil
Metronidazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Telbivudine
Metronidazole {u} may lead to a major life threatening interaction when taken with {v} Amprenavir
Metronidazole (Compound) resembles Tinidazole (Compound)
Metronidazole (Compound) binds CYP2C8 (Gene)
Metronidazole (Compound) upregulates ZNF586 (Gene)
Metronidazole (Compound) is included by Nitroimidazoles (Pharmacologic Class)
Metronidazole (Compound) causes Loss of libido (Side Effect)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Atomoxetine
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tetrabenazine
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil
Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine
Metronidazole may lead to a major life threatening interaction when taken with Amprenavir